PT1257276E - Derivados de azaindole antivirais - Google Patents

Derivados de azaindole antivirais

Info

Publication number
PT1257276E
PT1257276E PT01904970T PT01904970T PT1257276E PT 1257276 E PT1257276 E PT 1257276E PT 01904970 T PT01904970 T PT 01904970T PT 01904970 T PT01904970 T PT 01904970T PT 1257276 E PT1257276 E PT 1257276E
Authority
PT
Portugal
Prior art keywords
azaindole
antiviral derivatives
antiviral
derivatives
azaindole antiviral
Prior art date
Application number
PT01904970T
Other languages
English (en)
Portuguese (pt)
Inventor
Wang Tao
Owen B Wallace
Zhang Zhongxing
Nicholas A Meanwell
John A Bender
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22675206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1257276(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT1257276E publication Critical patent/PT1257276E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01904970T 2000-02-22 2001-01-19 Derivados de azaindole antivirais PT1257276E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18400400P 2000-02-22 2000-02-22

Publications (1)

Publication Number Publication Date
PT1257276E true PT1257276E (pt) 2006-05-31

Family

ID=22675206

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01904970T PT1257276E (pt) 2000-02-22 2001-01-19 Derivados de azaindole antivirais

Country Status (31)

Country Link
US (1) US20020061892A1 (enExample)
EP (1) EP1257276B1 (enExample)
JP (1) JP3868814B2 (enExample)
KR (1) KR100496574B1 (enExample)
CN (1) CN1404392A (enExample)
AR (1) AR029469A1 (enExample)
AT (1) ATE314072T1 (enExample)
AU (2) AU2001232895B2 (enExample)
BR (1) BRPI0108485B1 (enExample)
CA (1) CA2400700C (enExample)
CO (1) CO5271657A1 (enExample)
CY (1) CY1107460T1 (enExample)
DE (1) DE60116260T2 (enExample)
DK (1) DK1257276T3 (enExample)
EG (1) EG24669A (enExample)
ES (1) ES2254367T3 (enExample)
HU (1) HU229992B1 (enExample)
IL (1) IL150734A0 (enExample)
MX (1) MXPA02008113A (enExample)
MY (1) MY128458A (enExample)
NO (1) NO323564B1 (enExample)
NZ (1) NZ520317A (enExample)
PE (1) PE20020786A1 (enExample)
PL (1) PL357434A1 (enExample)
PT (1) PT1257276E (enExample)
RU (1) RU2259372C2 (enExample)
TR (1) TR200201961T2 (enExample)
TW (1) TWI293629B (enExample)
UY (1) UY26593A1 (enExample)
WO (1) WO2001062255A1 (enExample)
ZA (1) ZA200206073B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HU229305B1 (en) * 2001-02-02 2013-10-28 Bristol Myers Squibb Co Antiviral substituted azaindoleoxoacetic piperazine dervatives and compositions thereof
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
US20040162298A1 (en) * 2002-02-23 2004-08-19 Hsu-Tso Ho Method of treating HIV infection by preventing interaction of CD4 and gp120
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
CN1953985B (zh) * 2004-03-15 2010-06-09 布里斯托尔-迈尔斯斯奎布公司 哌嗪和取代的哌啶抗病毒药物的前药
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050252408A1 (en) * 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
HRP20090034T3 (en) 2004-06-09 2009-03-31 Glaxo Group Limited Pyrrolopyridine derivatives
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
CA2629232A1 (en) * 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101679358B (zh) * 2007-06-18 2013-10-30 塞诺菲-安万特股份有限公司 作为p2y12拮抗剂的吡咯衍生物
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
AU2009210296B2 (en) 2008-01-31 2013-11-14 Sanofi Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
SI2323633T1 (sl) * 2008-09-04 2012-07-31 Bristol Myers Squibb Co Stabilni farmacevtski sestavek za optimizirano razdeljevanje hiv pripetih inhibitorjev
JP5511942B2 (ja) 2009-04-03 2014-06-04 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト 組成物及びその使用
EP2496086B1 (en) 2009-11-06 2017-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
SI2672967T1 (sl) 2011-02-07 2018-12-31 Plexxikon Inc. Spojine in postopki za kinazno modulacijo in indikacije zanjo
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
EP2751119B1 (en) 2011-08-29 2016-11-23 VIIV Healthcare UK (No.5) Limited Fused bicyclic diamine derivatives as hiv attachment inhibitors
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN102746295B (zh) * 2012-06-20 2014-10-15 上海阿达玛斯试剂有限公司 4位取代-7-氮杂吲哚的制备方法
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
CN109528749B (zh) * 2017-09-22 2023-04-28 上海交通大学医学院附属瑞金医院 长链非编码rna-h19在制备治疗垂体瘤药物中的用途
IL301739A (en) 2020-10-05 2023-05-01 Enliven Therapeutics Inc 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases
CN118515629A (zh) * 2020-11-24 2024-08-20 中国人民解放军海军军医大学 一类取代苯甲酰哌嗪类化合物及其应用
CN115855899B (zh) * 2022-11-24 2025-06-10 常熟理工学院 一种荧光探针检测二氧化硫衍生物的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE142621T1 (de) * 1989-12-28 1996-09-15 Upjohn Co Diaromatische substituierte verbindungen gegen den aids-virus
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion

Also Published As

Publication number Publication date
CA2400700C (en) 2010-10-26
EP1257276A1 (en) 2002-11-20
DK1257276T3 (da) 2006-04-10
HUP0301508A2 (hu) 2003-09-29
HK1052132A1 (en) 2003-09-05
BRPI0108485B1 (pt) 2016-08-23
CN1404392A (zh) 2003-03-19
ATE314072T1 (de) 2006-01-15
KR20020073598A (ko) 2002-09-27
MY128458A (en) 2007-02-28
KR100496574B1 (ko) 2005-06-22
BR0108485A (pt) 2003-04-22
ES2254367T3 (es) 2006-06-16
TR200201961T2 (tr) 2002-12-23
JP2003523392A (ja) 2003-08-05
CO5271657A1 (es) 2003-04-30
EP1257276A4 (en) 2004-10-27
NZ520317A (en) 2004-05-28
WO2001062255A1 (en) 2001-08-30
NO323564B1 (no) 2007-06-11
CA2400700A1 (en) 2001-08-30
MXPA02008113A (es) 2003-01-28
PL357434A1 (en) 2004-07-26
DE60116260D1 (de) 2006-02-02
ZA200206073B (en) 2003-10-30
NO20023981D0 (no) 2002-08-21
EG24669A (en) 2010-04-11
HU229992B1 (en) 2015-04-28
JP3868814B2 (ja) 2007-01-17
UY26593A1 (es) 2001-09-28
DE60116260T2 (de) 2006-08-31
RU2259372C2 (ru) 2005-08-27
EP1257276B1 (en) 2005-12-28
AR029469A1 (es) 2003-07-02
AU3289501A (en) 2001-09-03
PE20020786A1 (es) 2002-09-06
CY1107460T1 (el) 2012-12-19
US20020061892A1 (en) 2002-05-23
TWI293629B (enExample) 2008-02-21
NO20023981L (no) 2002-10-17
HUP0301508A3 (en) 2004-08-30
IL150734A0 (en) 2003-02-12
RU2002125494A (ru) 2004-03-20
AU2001232895B2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
PT1257276E (pt) Derivados de azaindole antivirais
NO20010743D0 (no) Antivirale indoloksoacetyl-piperazin-derivater
ATE325807T1 (de) Purinderivate
DK1296996T3 (da) Purinderivater
DE60026861D1 (de) Purin-derivate
ATE238336T1 (de) Purin-derivate
EE200100681A (et) Puriinderivaadid
EE200300273A (et) Asendatud imidasopüridiinid
ATE372988T1 (de) Pyrimidin-derivate
PT1303521E (pt) Derivados de tetra-hidro-heterocicloazepinil-pirimidina
AR028602A1 (es) Derivados de pirrol
AR028282A1 (es) Derivados de aminofenil pirimidona
PT1246791E (pt) Derivados de aminometilfenilciclo-hexanona
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate